ArticleScience translational medicine2014
COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models.
Article in Science translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 227 citations in OpenAlex.
- Trial
- Dual-Action NSAID-Gold(I) Alkynyl Hybrids for Synergistic Anti-Inflammatory and Anticancer Therapy of Colorectal Cancer.Inorganic chemistry · 2026Article
- A unified therapeutic theory for treating cancer via master regulators of the universal apoptosis network.Cell death discovery · 2026Review
- Review
- Bevacizumab enhances overall survival in newly diagnosed glioblastoma patients with high COX-2 expression.Scientific reports · 2026Article
- Mast cell driven immunometabolism as a therapeutic entry point in ESCC.Frontiers in cell and developmental biology · 2026Review
- A review: advances of resveratrol co-delivery biomaterials-based system in anti-tumor therapy.Journal of materials science. Materials in medicine · 2025Review
- Recent advances in targeting COX-2 for cancer therapy: a review.RSC medicinal chemistry · 2025Review
- NSAID-encapsulated nanoparticles as a targeted therapeutic platform for modulating chronic inflammation and inhibiting cancer progression: a review.Inflammopharmacology · 2025Review
- Arachidonic acid in aging: New roles for old players.Journal of advanced research · 2025Review
- Expression of cyclooxygenase-2 (COX-2) in colorectal adenoma in an indigenous African population in northern Nigeria.African journal of laboratory medicine · 2025Article
- Caspase-4 promotes metastasis and interferon-γ-induced pyroptosis in lung adenocarcinoma.Communications biology · 2024Article
- Logistic PCA explains differences between genome-scale metabolic models in terms of metabolic pathways.PLoS computational biology · 2024Article
- Enhancing therapeutic efficacy in triple-negative breast cancer and melanoma: synergistic effects of modulated electro-hyperthermia (mEHT) with NSAIDs especially COX-2 inhibition in in vivo models.Molecular oncology · 2024Article
- Immune and stromal transcriptional patterns that influence the outcome of classic Hodgkin lymphoma.Scientific reports · 2024Article
- Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis.Acta pharmacologica Sinica · 2024Article
- Expression of cyclooxygenase-2 (COX-2) in colorectal carcinoma in an indigenous African population of Kano, Nigeria.Ecancermedicalscience · 2024Article
- COIMMR: a computational framework to reveal the contribution of herbal ingredients against human cancer via immune microenvironment and metabolic reprogramming.Briefings in bioinformatics · 2023Article
- Inhibitory effects of NSAID-conjugated SN-38 on the viability of A549 Non-small cell lung cancer cells.Biochemistry and biophysics reports · 2023Article
- Role of Leptin and Adiponectin in Carcinogenesis.Cancers · 2023Review
56 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
Antiangiogenic agents that block vascular endothelial growth factor (VEGF) signaling are important components of current cancer treatment modalities but are limited by alternative ill-defined angiogenesis mechanisms that allow persistent tumor vascularization in the face of continued VEGF pathway blockade. We identified prostaglandin E2 (PGE2) as a soluble tumor-derived angiogenic factor associated with VEGF-independent angiogenesis. PGE2 production in preclinical breast and colon cancer models was tightly controlled by cyclooxygenase-2 (COX-2) expression, and COX-2 inhibition augmented VEGF pathway blockade to suppress angiogenesis and tumor growth, prevent metastasis, and increase overall survival. These results demonstrate the importance of the COX-2/PGE2 pathway in mediating resistance to VEGF pathway blockade and could aid in the rapid development of more efficacious anticancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.